Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $46.22 and last traded at $44.86, with a volume of 1685189 shares trading hands. The stock had previously closed at $39.12.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on DNTH shares. Truist Financial lifted their price target on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Wedbush reaffirmed an “outperform” rating and issued a $46.00 target price on shares of Dianthus Therapeutics in a research note on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright lifted their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $64.43.

Dianthus Therapeutics Stock Down 4.9%

The stock has a market cap of $1.89 billion, a price-to-earnings ratio of -12.64 and a beta of 1.55. The stock has a fifty day moving average of $41.43 and a two-hundred day moving average of $32.70.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $152,560. The trade was a 96.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total transaction of $903,600.00. The SEC filing for this sale provides additional information. Insiders sold 216,538 shares of company stock worth $8,283,175 in the last 90 days. 8.15% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Fairmount Funds Management LLC boosted its position in shares of Dianthus Therapeutics by 22.2% in the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after buying an additional 600,000 shares during the period. Vestal Point Capital LP lifted its position in Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares during the period. TCG Crossover Management LLC boosted its holdings in Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after acquiring an additional 175,000 shares during the period. Finally, Vanguard Group Inc. grew its position in Dianthus Therapeutics by 13.6% in the third quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock valued at $64,620,000 after acquiring an additional 196,117 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.